Efficacy of pretreatment D-chiro-inositol and cyproterone acetate-ethinyl estradiol combination therapy compared to cyproterone acetate-ethinyl estradiol alone for ovarian response in polycystic ovary syndrome with high AMH

Abanti Ghosh; Lipi Rany Saha; Fawzia Hossain; Humaira Alam; Mostafa M. Al Tarique; Rebeka Sultana; Arati Sharma; Jesmine Banu

doi:10.18203/2320-1770.ijrcog20252340

Authors

Abanti Ghosh Department of Reproductive Endocrinology and Infertility (OSD), Bangladesh Medical University, Dhaka, Bangladesh
Lipi Rany Saha Department of Reproductive Endocrinology and Infertility (OSD), Bangladesh Medical University, Dhaka, Bangladesh
Fawzia Hossain Department of Gynaecological Oncology, Bangladesh Medical University, Dhaka, Bangladesh
Humaira Alam Department of Reproductive Endocrinology and Infertility, Bangladesh Medical University, Dhaka, Bangladesh
Mostafa M. Al Tarique Department of Reproductive Endocrinology and Infertility, Bangladesh Medical University, Dhaka, Bangladesh
Rebeka Sultana Department of Reproductive Endocrinology and Infertility (OSD), Bangladesh Medical University, Dhaka, Bangladesh
Arati Sharma Department of Reproductive Endocrinology and Infertility, Bangladesh Medical University, Dhaka, Bangladesh
Jesmine Banu Department of Reproductive Endocrinology and Infertility, Bangladesh Medical University, Dhaka, Bangladesh

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20252340

Keywords:

Cyproterone acetate ethinyl estradiol, D chiro-inositol, Polycystic ovary syndrome

Abstract

Background: Polycystic ovary syndrome (PCOS) is a leading cause of anovulatory infertility, often associated with elevated AMH levels. This study evaluates whether adding D-chiro-inositol to cyproterone acetate–ethinyl estradiol improves ovarian response in PCOS women with high AMH. To assess the effects of pre-treatment with D-chiro-inositol and Cyproterone acetate-ethinyl estradiol compared to Cyproterone acetate-ethinyl estradiol alone for ovarian response in high AMH patient of PCOS.

Methods: This open-label randomized controlled trial was conducted at the Department of Reproductive Endocrinology and Infertility, Bangabandhu Sheikh Mujib Medical University (BSMMU), Shahbagh, Dhaka, from July 2023 to June 2024. Sixty sub-fertile women with PCOS were randomized into two groups (n=30). Data were analyzed using SPSS version 25.0 and comparisons between groups were made using the Chi-square test, t-test or Mann-Whitney U test as appropriate. A p-value of <0.05 was considered statistically significant.

Results: Serum AMH and LH levels significantly decreased in both groups, with no significant difference between them. Although the experimental group showed a slightly higher ovarian response (74.07% compared to 69.23% in cycle 1; 76.92% compared to 72.73% in cycle 2), this was not statistically significant. Similarly, cumulative ovulation and pregnancy rates did not differ significantly between groups.

Conclusions: Pre-treatment with D-chiro-Inositol and cyproterone acetate–ethinyl estradiol combination therapy compared to cyproterone acetate–ethinyl estradiol alone, provides similar efficacy in terms of hormonal profile changes, ovarian response, cumulative ovulation rate and cumulative pregnancy rate in PCOS with high AMH.

Metrics

Metrics Loading ...

References

Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera M. A combined therapy with myo‐inositol and D‐chiro‐inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. Int J Endocrinol. 2016;2(1):3204083. DOI: https://doi.org/10.1155/2016/3204083

Banu J, Ishrat S, Deeba F, Anowary S, Alamgir CF, Darmini M. Impact of Cyproterone Acetate and Ethinylestradiol on Clomiphene Resistant PCOS Patient with High Serum AMH level. J Shaheed Suhrawardy Medical Coll. 2020;12(1):38-44. DOI: https://doi.org/10.3329/jssmc.v12i1.51617

Villarroel C, Merino PM, Lopez P, Eyzaguirre FC, Van Velzen A, Iniguez G, et al. Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Müllerian hormone. Human Reprod. 2011;1;26(10):2861-8. DOI: https://doi.org/10.1093/humrep/der223

Begum MR, Ehsan M, Ehsan N. Value of Assessing AMH in the Management of Polycystic Ovarian Syndrome (PCOS). Bangladesh J Obstet Gynaecol. 2022;37(1):47-62. DOI: https://doi.org/10.3329/bjog.v37i1.68789

Amer SA, Mahran A, Abdelmaged A, El-Adawy AR, Eissa MK, Shaw RW. The influence of circulating anti-Müllerian hormone on ovarian responsiveness to ovulation induction with gonadotrophins in women with polycystic ovarian syndrome: a pilot study. Reproductive Biol Endocrinol. 2013;11:1-9. DOI: https://doi.org/10.1186/1477-7827-11-115

Mahran A, Abdelmeged A, El-Adawy AR, Eissa MK, Shaw RW, Amer SA. The predictive value of circulating anti-Müllerian hormone in women with polycystic ovarian syndrome receiving clomiphene citrate: a prospective observational study. The Journal of Clin Endocrinol Metabol. 2013;1;98(10):4170-5. DOI: https://doi.org/10.1210/jc.2013-2193

Lanham MS, Prochaska EC, Smith Y. Elevated anti-müllerian hormone (AMH) levels decrease odds of response to ovulation induction with letrozole or clomiphene citrate. Fert Ster. 2014;102(3):22. DOI: https://doi.org/10.1016/j.fertnstert.2014.07.083

Chowdhury P, Banu J, Deeba F, Debnath RC, Rani C, Sultana S. Pre-treatment with cyproterone acetate plus ethinyl estradiol enhances ovarian response in women with polycystic ovary syndrome. Int J Reprod Contracept Obstet Gynecol. 2023;12:2889–95. DOI: https://doi.org/10.18203/2320-1770.ijrcog20232855

Laganà AS, Forte G, Bizzarri M, Kamenov ZA, Bianco B, Kaya C, et al. Inositols in the ovaries: activities and potential therapeutic applications. Expert Opinion on Drug Metabol Toxicol. 2022;1;18(2):123-33. DOI: https://doi.org/10.1080/17425255.2022.2071259

Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S, et al. Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metabol. 2007;1;92(1):240-5. DOI: https://doi.org/10.1210/jc.2006-1582

Catteau‐Jonard S, Bancquart J, Poncelet E, Lefebvre‐Maunoury C, Robin G, Dewailly D. Polycystic ovaries at ultrasound: normal variant or silent polycystic ovary syndrome. Ultr Obstet Gynecol. 2012;40(2):223-9. DOI: https://doi.org/10.1002/uog.11202

Alebić MŠ, Stojanović N, Duhamel A, Dewailly D. The phenotypic diversity in per-follicle anti-Müllerian hormone production in polycystic ovary syndrome. Human Reproduct. 2015;30(8):1927-33. DOI: https://doi.org/10.1093/humrep/dev131

Cimino I, Casoni F, Liu X, Messina A, Parkash J, Jamin SP, et al. Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion. Nature Commu. 2016;7(1):10055. DOI: https://doi.org/10.1038/ncomms10055

Panidis D, Georgopoulos NA, Piouka A, Katsikis I, Saltamavros AD, Decavalas G, et al. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gynecol Endocrinol. 2011;27(8):587-92. DOI: https://doi.org/10.3109/09513590.2010.507283

Pericuesta E, Laguna-Barraza R, Ramos-Ibeas P, Gutierrez-Arroyo JL, Navarro JA, Vera K, Sanjuan C, et al. D-chiro-inositol treatment affects oocyte and embryo quality and improves glucose intolerance in both aged mice and mouse models of polycystic ovarian syndrome. Int J Molecular Sci. 2020;22;21(17):6049. DOI: https://doi.org/10.3390/ijms21176049

Gambioli R, Forte G, Aragona C, Bevilacqua A, Bizzarri M, Unfer V. The use of D-chiro-Inositol in clinical practice. European Rev Med and Pharmacol Sci. 2021;25(1):438-46.

Wojciechowska A, Osowski A, Jóźwik M, Górecki R, Rynkiewicz A, Wojtkiewicz J. Inositols’ importance in the improvement of the endocrine–metabolic profile in PCOS. International J Molec Sci. 2019;18;20(22):5787. DOI: https://doi.org/10.3390/ijms20225787

Taylor HS, Pal L, Sell E. Speroff's clinical gynecologic endocrinology and infertility. Lippincott Williams & Wilkins. 2019.

Kar S. Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile PCOS women: A prospective randomized trial. J Human Reprod Sci. 2012;5(3):262-5. DOI: https://doi.org/10.4103/0974-1208.106338

Franik S, Kremer JA, Nelen WL, Farquhar C. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2014(2):76547. DOI: https://doi.org/10.1002/14651858.CD010287.pub2

Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. New England J Med. 2014;371(2):119-29. DOI: https://doi.org/10.1056/NEJMoa1313517

Ran Y, Yi Q, Li C. The relationship of anti-mullerian hormone in polycystic ovary syndrome patients with different subgroups. Diabetes, Metab Syndr Obes. 2021;25:1419-24. DOI: https://doi.org/10.2147/DMSO.S299558

Larner J, Brautigan DL, Thorner MO. D-chiro-inositol glycans in insulin signaling and insulin resistance. Mole Med. 2010;16:543-52. DOI: https://doi.org/10.2119/molmed.2010.00107

Akhter D, Banu J, Yasmin M, Sultana N, Munmun SA. Effect of D-chiro-inositol on hormonal parameters and insulin resistance in women with polycystic ovary syndrome. Int J Reprod Contracept Obstet Gynecol. 2023;12(7):1992–7. DOI: https://doi.org/10.18203/2320-1770.ijrcog20231909

Genazzani AD, Santagni S, Rattighieri E, Chierchia E, Despini G, Marini G, et al. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrino. 2014;30(6):438-43. DOI: https://doi.org/10.3109/09513590.2014.897321

Pizzo A, Lagana AS, Barbaro L. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol. 2014;30(3):205-8. DOI: https://doi.org/10.3109/09513590.2013.860120

La Marca A, Grisendi V, Dondi G, Sighinolfi G, Cianci A. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol. 2015;31(1):52-6. DOI: https://doi.org/10.3109/09513590.2014.964201

Galazis N, Galazi M, Atiomo W. D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review. Gynecol Endocrinol. 2011;27(4):256-62. DOI: https://doi.org/10.3109/09513590.2010.538099

Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endo Pract. 2002;8(6):417-23. DOI: https://doi.org/10.4158/EP.8.6.417

Chen Z, Tan J, Wang H, Zheng B, Liu J, Hao G, et al. A randomized cohort study: is it worth the time to receive antiandrogenic Pre-treatment before ovulation induction for women with polycystic ovary syndrome. Front Endocrin. 2022;13:813188. DOI: https://doi.org/10.3389/fendo.2022.813188

Unfer V, Carlomagno G, Rizzo P, Raffone E, Roseff S. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. European Rev Med Pharmacol Sci. 2011;1;15(4):76.